Experiences of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice
https://doi.org/10.21516/2072-0076-2018-11-4-80-85
Abstract
Purpose. To assess the effectiveness and safety of intravitreal aflibercept injections in clinically significant diabetic macular edema (DME) in a routine clinical practice.
Material and methods. This was a prospective, observational, single-center study. During the study, anti-VEGF treatment naïve patients with clinically significant DME received five monthly intravitreal injections of aflibercept 2 mg followed by bimonthly injections. The observation period was 1 year.
Results. The study included 11 eyes of 10 patients with clinically significant DME. Use of 8 intravitreal aflibercept injections resulted in central retinal thickness (CRT) reduction by 50 % from the baseline within 1 year of therapy. CRT decreased on average from 446.18 ± 106.88 μm to 226.27 ± 44.56 μm by the end of observational period. In addition, an increase in visual acuity was observed from an average from 0.33 ± 0.22 at the start of therapy to 0.62 ± 0.33 at the end of the observation. Serious adverse events over the entire period of treatment were not observed.
Conclusion. Aflibercept showed high efficacy and safety in the treatment of clinically significant DME in routine clinical practice. To obtain optimal functional and morphological results in the treatment of patients with DME, it is necessary to start therapy with 5 loading intravitreal aflibercept injections.
About the Author
E. Yu. Santoro
Surgut medical institute,
Surgut regional clinical hospital
Russian Federation
Russian Federation
Cand. Med. Sci., ophthalmologist, assistant professor, chair of surgical diseases, head of diabetic ophthalmopathy center
14, Energetikov st., Surgut, 628400, Russia
References
1. Астахов Ю.С., Нечипоренко П.А. Лечение афлиберцептом больных с диабетическим макулярным отеком. Офтальмологические ведомости. 2017; 10 (2): 94–109. Astakhov Yu.S., Nechiporenko P.A. Aflibercept treatment in patients with diabetic macular edema. Ophthalmology Journal. 2017; 10 (2): 94–109 (in Russian). doi: 10.17816/OV10294-109
2. Охоцимская Т.Д., Зайцева О.В. Афлиберцепт в лечении заболеваний сетчатки. Обзор клинических исследований. Российский офтальмологический журнал. 2017; 10 (2): 103–11. Okhotsimskaya T.D., Zaitseva O.V. Aflibercept for the therapy of retinal diseases. A review of clinical studies. Russian ophthalmological journal. 2017; 10 (2): 103–11 (in Russian). doi: 10.21516/2072-0076-2017-10-2-103-111
3. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009; 20 (4): 158–63. doi: 10.1684/ecn.2009.0170
4. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2009; Feb 24; 2 (59): re1. doi: 10.1126/scisignal.259re1
5. Исхакова А.Г., Золотарев А.В., Викторов Д.А., Тороповский А.Н., Никитин А.Г. Роль факторов роста сосудов в развитии диабетической ретинопатии и макулярного отека. Российский офтальмологический журнал. 2018;
6. (2): 62–9. doi: 10.21516/2072-0076-2018-11-2-62-69 Iskhakova A.G., Zolotarev A.V., Viktorov D.A., Toropovsky A.N., Nikitin A.G. The role of vascular growth factors in diabetic retinopathy and macular edema development. Russian ophthalmological journal. 2018; 11 (2): 62–9 (in Russian). doi: 10.21516/2072-0076-2018-11-2-62-69
7. Mitamura Y., Tashimo A, Nakamura Y., et al. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care. 2002 (25): 2352. https://doi.org/10.2337/diacare.25.12.2352
8. Ando R., Noda K., Namba S., et al. Aqueous humour levels of placental growth factor in diabetic retinopathy. Acta Ophthalmol. 2014 (92): e245–246. doi: 10.1111/aos.12251
9. Miyamoto N., de Kozak Y., Jeanny J., et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia. 2007 (50): 461–70. doi: 10.1007/s00125-006-0539-2
10. Kowalczuk L., Touchard E., Omri S., et al. Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PloS One. 2011(6):e17462. doi: 10.1371/journal.pone.0017462
11. Papadopoulos N., Martin J., Ruan Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15 (2): 171–85. doi: 10.1007/s10456-011-9249-6
12. Korobelnik J.F., Do D.V., Schmidt-Erfurth U., et al. Intravitreal Aflibercept for Diabetic Macular Edema. Ophthalmology. 2014; 121: 2247–54. doi: 10.1016/j.ophtha.2014.05.006
13. Heier J.S., Korobelnik J.F., Brown D.M., et al. Intravitreal Aflibercept for diabetic macular edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016; 123 (11): 2376–85. doi: 10.1016/j.ophtha.2016.07.032
14. Wells J.A., Glassman A.R., Ayala A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med. 2015 Mar 26; 372 (13): 1193–203. doi: 10.1056/NEJMoa1414264
15. Wells J.A., Glassman A.R., Ayala A.R., et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016; 123: 1351–9. doi: 10.1016/j.ophtha.2016.02.022
16. Jampol L.M., Glassman A.R., Bressler N.M., et al. Anti–Vascular Endothelial Growth Factor comparative effectiveness trial for diabetic macular edema. Additional efficacy post hoc analyses of a randomized clinical trial. JAMA Ophthalmol. 2016 Dec 1; 134 (12). doi: 10.1001/jamaophthalmol.2016.3698
17. Ziemssen F., Schlottman PG., Lim J.I., et al. Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID DME and VISTA DME data. Int. J. Retina Vitreous. 2016 Jul 11; 2: 16. doi: 10.1186/s40942-016-0041-z
18. Инструкция по применению лекарственного препарата для медицинского применения Эйлеа. ЛП-003544 от 19.09.2017. Instruction for medical using of Eilea. LP-003544, 19.09.2017 (in Russian).
Review
For citations:
Santoro E.Yu. Experiences of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice. Russian Ophthalmological Journal. 2018;11(4):80-86. (In Russ.) https://doi.org/10.21516/2072-0076-2018-11-4-80-85
Views:
1069
Email this article 